成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

ChemicalBook--->CAS DataBase List--->2216753-97-6

2216753-97-6

2216753-97-6 Structure

2216753-97-6 Structure
IdentificationBack Directory
[Name]

3-Pyridineacetamide, 6-(6,7-dimethoxy-3-quinolinyl)-N-[3-(2,2,2-trifluoro-1,1-dimethylethyl)-5-isoxazolyl]-
[CAS]

2216753-97-6
[Synonyms]

DS-5010
BOS-172738
Zeteletinib
Zeteletinib( BOS-172738)
3-Pyridineacetamide, 6-(6,7-dimethoxy-3-quinolinyl)-N-[3-(2,2,2-trifluoro-1,1-dimethylethyl)-5-isoxazolyl]-
[Molecular Formula]

C25H23F3N4O4
[MOL File]

2216753-97-6.mol
[Molecular Weight]

500.47
Chemical PropertiesBack Directory
[Boiling point ]

661.1±55.0 °C(Predicted)
[density ]

1.330±0.06 g/cm3(Predicted)
[storage temp. ]

Store at -20°C
[form ]

Solid
[pka]

12.23±0.70(Predicted)
[color ]

White to light yellow
Hazard InformationBack Directory
[Uses]

Zeteletinib (BOS-172738; DS-5010) is an orally active, selective RET kinase inhibitor with nanomolar potency against RET and >300-fold selectivity against VEGFR2. Zeteletinib shows exquisite potency for the wild type RET, RETV804M/L gatekeeper mutants, and the most common oncogenic RET mutation M918T. Zeteletinib has potent antitumor activity[1][2][3].
[in vivo]

In a Ba/F3-RET subcutaneous tumor model, Zeteletinib (BOS-172738; DS-5010) dosing at 10 mg/kg twice daily (bid) induces tumor regression[1].
In an LC2/ad NSCLC xenograft model, which has the RET-CCDC6 fusion gene, Zeteletinib dosing at 1 mg/kg thrice daily (tid) induced tumor regression[1].

[IC 50]

PDGFR2
[References]

[1] Yasuyuki Kaneta, et al.Abstract B173: Preclinical characterization and antitumor efficacy of DS-5010, a highly potent and selective RET inhibitor. MOLECULAR CANCERTHERAPEUTICS. January 2018, Volume 17, Issue 1.
[2] Patrick Schoffski, et al. BOS172738, a highly potent and selective RET inhibitor, for the treatment of RET-altered tumors including RET-fusion+ NSCLC and RET-mutant MTC: Phase 1 study results. Journal of Clinical Oncology 39, no. 15_suppl (May 20, 2021) 3008-3008.
[3] Kyaw Z Thein, et al. Precision therapy for RET-altered cancers with RET inhibitors. Trends Cancer. 2021 Dec;7(12):1074-1088. DOI:10.1016/j.trecan.2021.07.003
2216753-97-6 suppliers list
Company Name: Guangzhou Younan Technology Co., Ltd  
Tel: 020-82000279 18988968278
Website: http://www.ubiochem.cn/
Company Name: Nantong QuanYi Biotechnology Co., Ltd  
Tel: 0513-66337626 18051384581
Website: https://www.chemhifuture.com/
Company Name: mahaloong  
Tel: +86-028-81192082 +86-18180560816
Website: https://www.mahaloong.com
Company Name: RD International Technology Co., Limited  
Tel: 18024082417
Website: www.ruidiresearch.com
Tags:2216753-97-6 Related Product Information

  • HomePage | Member Companies | Advertising | Contact us | Previous WebSite | MSDS | CAS Index | CAS DataBase | Privacy | Terms | About Us
  • All products displayed on this website are only for non-medical purposes such as industrial applications or scientific research, and cannot be used for clinical diagnosis or treatment of humans or animals. They are not medicinal or edible.
    According to relevant laws and regulations and the regulations of this website, units or individuals who purchase hazardous materials should obtain valid qualifications and qualification conditions.
  • Copyright © 2023 ChemicalBook All rights reserved.